Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-24-100027
Filing Date
2024-08-23
Accepted
2024-08-23 08:55:17
Documents
6
Period of Report
2024-08-23

Document Format Files

Seq Description Document Type Size
1 6-K 6-k_registered_direct_au.htm 6-K 40509
2 EX-4.1 vrax-ex4_1.htm EX-4.1 151563
3 EX-5.1 vrax-ex5_1.htm EX-5.1 63083
4 EX-10.1 vrax-ex10_1.htm EX-10.1 308394
5 EX-99.1 vrax-ex99_1.htm EX-99.1 16790
6 GRAPHIC img35431341_0.jpg GRAPHIC 1944
  Complete submission text file 0000950170-24-100027.txt   584375
Mailing Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH
Business Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH 44 020 7788 7414
Virax Biolabs Group Ltd (Filer) CIK: 0001885827 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-41440 | Film No.: 241233623
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)